Publications [#275174] of John S. March

Papers Published

1. JM Swanson, GR Elliott, LL Greenhill, T Wigal, LE Arnold, B Vitiello, L Hechtman, JN Epstein, WE Pelham, HB Abikoff, JH Newcorn, BS Molina, SP Hinshaw, KC Wells, B Hoza, PS Jensen, RD Gibbons, K Hur, A Stehli, M Davies, JS March, CK Conners, M Caron and ND Volkow (2007). Effects of stimulant medication on growth rates across 3 years in the MTA follow-up.. J Am Acad Child Adolesc Psychiatry, 46(8), 1015-1027. [17667480], [doi]
   (last updated on 2016/01/27)

   Abstract:
   OBJECTIVE: To evaluate the hypothesis of stimulant medication effect on physical growth in the follow-up phase of the Multimodal Treatment Study of Children With ADHD. METHOD: Naturalistic subgroups were established based on patterns of treatment with stimulant medication at baseline, 14-, 24-, and 36-month assessments: not medicated (n = 65), newly medicated (n = 88), consistently medicated (n = 70), and inconsistently medicated (n = 147). Analysis of variance was used to evaluate effects of subgroup and assessment time on measures of relative size (z scores) obtained from growth norms. RESULTS: The subgroup x assessment time interaction was significant for z height (p <.005) and z weight (p <.0001), due primarily to divergence of the newly medicated and the not medicated subgroups. These initially stimulant-naïve subgroups had z scores significantly >0 at baseline. The newly medicated subgroup showed decreases in relative size that reached asymptotes by the 36-month assessment, when this group showed average growth of 2.0 cm and 2.7 kg less than the not medicated subgroup, which showed slight increases in relative size. CONCLUSIONS: Stimulant-naïve school-age children with Combined type attention-deficit/hyperactivity disorder were, as a group, larger than expected from norms before treatment but show stimulant-related decreases in growth rates after initiation of treatment, which appeared to reach asymptotes within 3 years without evidence of growth rebound.